Motif is committed to helping resolve the looming public health crisis by developing novel antibiotics designed to be effective against multi-drug resistant bacteria. Our initial focus is on iclaprim, which may offer a rapid path to commercialization.

 Iclaprim

Iclaprim is an antibiotic with a unique mechanism of action that we believe to be effective against multi-drug resistant bacteria. Iclaprim may offer a rapid path to market with commercialization possible as early as 2018.

About Iclaprim

 Other Programs

Motif intends to build a portfolio of novel antibiotics by licensing drug candidates from organizations specializing in antibacterial research. Motif is pursuing several programs in various stages of development.

The Opportunity